Enterolactone has stronger effects than enterodiol on ovarian cancer

@inproceedings{Liu2017EnterolactoneHS,
  title={Enterolactone has stronger effects than enterodiol on ovarian cancer},
  author={Huidi Liu and Jianrui Liu and Siwen Wang and Zheng Zeng and Ting Li and Yongfang Liu and Emilio Mastriani and Qing-hai Li and Hong-xia Bao and Yujie Zhou and Xiaoyu Wang and Sijing Hu and Shan Gao and Yingying Qi and Zhihang Shen and Hongyue Wang and Miao Yu and Tingting Gao and Randal N Johnston and Shu-lin Liu},
  booktitle={Journal of ovarian research},
  year={2017}
}
BACKGROUND Ovarian cancer is one of the three leading gynecological malignancies, characterized by insidious growth, highly frequent metastasis, and quick development of drug resistance. As a result, this disease has low 5-year survival rates. Estrogen receptor inhibitors were commonly used for the treatment, but only 7% to 18% of patients respond to anti-estrogen therapies. Therefore, more effective therapies to inhibit estrogen-related tumors are urgently needed. Recently, phytoestrogens… CONTINUE READING